KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Free Cash Flow: 2018-2025

Historic Free Cash Flow for Castle Biosciences (CSTL) over the last 7 years, with Sep 2025 value amounting to $7.8 million.

  • Castle Biosciences' Free Cash Flow fell 54.03% to $7.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.4 million, marking a year-over-year decrease of 26.52%. This contributed to the annual value of $36.5 million for FY2024, which is 289.85% up from last year.
  • Latest data reveals that Castle Biosciences reported Free Cash Flow of $7.8 million as of Q3 2025, which was down 32.54% from $11.6 million recorded in Q2 2025.
  • Castle Biosciences' Free Cash Flow's 5-year high stood at $26.9 million during Q4 2021, with a 5-year trough of -$38.9 million in Q2 2021.
  • In the last 3 years, Castle Biosciences' Free Cash Flow had a median value of $7.8 million in 2025 and averaged $2.4 million.
  • The largest annual percentage gain for Castle Biosciences' Free Cash Flow in the last 5 years was 2,741.81% (2021), contrasted with its biggest fall of 483.36% (2021).
  • Quarterly analysis of 5 years shows Castle Biosciences' Free Cash Flow stood at $26.9 million in 2021, then crashed by 128.93% to -$7.8 million in 2022, then soared by 289.98% to $14.8 million in 2023, then climbed by 13.55% to $16.8 million in 2024, then slumped by 54.03% to $7.8 million in 2025.
  • Its Free Cash Flow stands at $7.8 million for Q3 2025, versus $11.6 million for Q2 2025 and -$10.8 million for Q1 2025.